Rigel has an exclusive license and supply agreement with Knight to commercialize TAVALISSE (fostamatinib disodium hexahydrate) in all potential indications in Latin America.
As of February 2024, Knight had submitted marketing authorization applications for TAVALISSE in Brazil, Colombia and Mexico.
Knight announced Mexico's Comisión Federal para la Protección contra Riesgos Sanitarios approved TAVALISSE for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment in December 2024.
Rigel received an upfront cash payment, with the potential for additional regulatory and commercial milestones, and stepped-up royalties based on tiered net sales.